St Herblain, France, September 27, 2021 — L’Institut de Cancérologie de l’Ouest (ICO), one of the leading provincial cancer centers in France, has joined the TriNetX global health research network to facilitate innovative patient care, promote clinical research, and support optimization of therapeutic strategies.
“ICO is the first cancer center to join the TriNetX Network in France, which is a significant milestone for both organizations, our investigators, and our patients who will benefit from increased access to clinical trials and collaborative research opportunities,” said Guillaume Mercusot, Director of Innovation and Development at ICO.
The TriNetX platform enables investigators to harness the potential of harmonized global real-world data and cutting-edge analytics to accelerate research and the generation of real-world evidence while simultaneously protecting patient privacy through the GDPR, LGPD, and HIPAA-compliant federated research network.
“As a member of the TriNetX Network, ICO is now connected to a dense, international community of pharmaceutical companies and peer research institutions that will increase the visibility of ICO and facilitate collaborative clinical research and real-world evidence studies,” continued Mercusot.
“TriNetX is delighted to be part of ICO’s strategy to better leverage real-world data, analytics, and relationships with industry leaders and healthcare organizations all over the world to strengthen its research capabilities,” said Olivier Denquin, Regional Partnerships Manager, France at TriNetX.
“TriNetX is looking forward to supporting ICO’s research goals and ultimately bringing additional value to its patients and investigators,” said Steve Lethbridge, Senior Vice President of Global Healthcare Partnerships at TriNetX.
About L’Institut de Cancérologie de l’Ouest (ICO)
The Western Cancer Institute (ICO – L’Institut de Cancérologie de l’Ouest) is a leading cancer center with international expertise, fueled by a dynamic of innovation—both in the advancement of innovative therapies and in revolutionizing the use of data and technology in treatment. With nearly one hundred years of experience, ICO treats more than 46,000 cancer patients each year across two sites in St Herblain and Angers in Pays de la Loire, France. ICO is the largest cancer center in its region, and the third nationally. ICO is the leading radiotherapy center in France, averaging 99,000 sessions per year and is a pioneer in the field of breast reconstruction. For more information, visit ICO at https://www.institut-cancerologie-ouest.com
About TriNetX, LLC
TriNetX is a global network of healthcare organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA, GDPR, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, and enrich real-world evidence generation. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.
L’Institut de Cancérologie de l’Ouest (ICO)
+33 (0) 2-40-67 98-68
+1 (857) 285-6037